Summary: Interleukin 1, a multifunctional cytokine, plays a central role in inflammatory processes and induction of the immune response. Target cells possess 200 -5000 (or more) interleukin 1 receptors per cell, but they exhibit a full biological response when only 1 -2% of these receptors are occupied by interleukin la or I . Methotrexate has been reported to be beneficial in several inflammatory and autoimmune diseases. On the other hand, many of these diseases are known to share an overproduction of interleukin 1. It has been demonstrated that methotrexate has no influence on the interleukin 1 synthesis, so we focused our attention on the ability of methotrexate to interfere with the binding of interleukin 1 β to the interleukin 1 receptor. The experiments were performed on monocytes, lymphocytes and granulocytes using a recombinant human cytokine probe. Methotrexate led to an astonishing decrease in the binding of interleukin 1 β to the interleukin 1 receptor of peripheral blood cells, whereas methylprednisolone and indomethacin were not inhibitory. The inhibitory effect of methotrexate was dose dependent. An excess of interleukin I abolished the inhibition of cytokine binding by methotrexate. We also demonstrated that methotrexate does not affect the integrity of the interleukin 1 receptor or of the target cells. Our results demonstrate that methotrexate blocks the interleukin l -interleukin 1 receptor pathway. Methotrexate is therefore another interleukin 1 inhibitor and a clinically efficient anticytokine. but exert a full biological effect when only 1 -2% of Interleukin 1 is represented by two distinct cytokines, these receptors are occupied by interleukin 1 (2). interleukin la and interleukin I polypeptides, which ^ ,11·,.,
but exert a full biological effect when only 1 -2% of Interleukin 1 is represented by two distinct cytokines, these receptors are occupied by interleukin 1 (2) . interleukin la and interleukin I polypeptides, which ^ ,11·,., , ., · ι*. , · , · synthesis and the regulation of signal transduction by cytokines have identical biological properties. · r ·*ι. *ιΓ u· j-*· * ι Ί· 4 0 ^ ^ interference with the binding of interleukin 1 to its Binding studies in a variety of cells have shown that receptor on target cells. The binding of interleukin 1 interleukin la exhibits a greater affinity to the inter-to the interleukin 1 receptor is prevented by natural leukin 1 receptor type I (M T 80 000) and interleukin 1 β interleukin 1 inhibitors such as the interleukin 1 reexerts a greater affinity to the interleukin 1 receptor ceptor antagonist, which competes with interleukin 1 type II (M T 60 000). The interleukin 1 receptor type I for the interleukin 1 receptor, or by the soluble interis found on T-cells, fibroblasts, keratinocytes, endo-leukin 1 receptor which binds directly to interleukin 1 thelial cells and chondrocytes; the interleukin 1 recep-(1, 2). Other described interleukin 1 inhibitors are tor type II is found on B-cells, neutrophils and mono-epidermal cell-contra-interleukin 1 which is induced cytes (1) . It has been reported that target cells possess by UV-B radiation in the epidermis (3) , and the cy-200-5000 (ore more) interleukin 1 receptors per cell tokine transforming growth factor l (4). Because of the great affinity of the target cells for interleukin 1, an excess of interleukin 1 receptor antagonist must be present to block the interleukin 1-induced biological responses.
Independent of its antiproliferative effect in high doses (5, 6) , methotrexate (4-amino-4-deoxy-N10-methylpteroylglutamic acid) exerts well documented antiinflammatory and immunoregulatory activity in low doses, but its mechanism of action is not clear.
While methotrexate has no demonstrable influence on the interleukin 1 production (7) and at the same time there are clinical and experimental references to an antiinflammatory function of methotrexate, the question arises whether it might act via interleukin 1 antagonism. We focussed our attention on the binding of interleukin 1 β to its receptor on target cells in the presence of methotrexate, in order to examine whether methotrexatahas the ability to block the interleukin 1-interleukin 1 receptor pathway.
Materials and Methods

Materials
Phycoerythrin labelled human interleukin I was obtained from Hermann Biermann Diagnostica GmbH Bad Nauheim, Germany, methotrexate was obtained from Lederle GmbH & Co. Wolfratshausen, Germany, methylprednisolone (Urbason®) from Hoechst AG Frankfurt a. M., Germany, indomethacin (Vonum®) from Econerica GmbH Puchheim/M nchen, Germany. Phycoerythrin-labelled monoclonal antibodies: mouse anti-human CDS, mouse anti-human CD4, mouse anti-human CDllb, mouse anti-human CD14, mouse anti-human CD19, mouse anti-human CD25 were obtained from Becton Dickinson GmbH Heidelberg, Germany. The flow cytometer (FACScan) apparatus and FACS lysing solution were from Becton Dickinson GmbH Heidelberg, Germany.
Cytokine probe -principle of the method Cells were incubated with phycoerythrin labelled interleukin 1 β which bound to specific cellular interleukin 1 receptors. Unbound interleukin I was then washed from the cells. Cells expressing the interleukin 1 receptor were fluorescently stained. The intensity of fluorescence was directly proportional to the density of the receptors. Phycoerythrin labelled interleukin lbinding receptor density was then determined by FACS analysis using 488 nm wavelength laser excitation. The specificity of the reaction of phycoerythrin labelled interleukin I was demonstrated by blocking the staining of the cells by pretreatment with a 100-fold molar excess of unlabeled interleukin I prior to incubation with phycoerythrin labelled interleukin I .
The binding ability of interleukin I to the interleukin 1 receptor on monocytes, lymphocytes and granulocytes was analysed in blood samples from twenty-five healthy volunteers as follows:
Interleukin I binding assay
Whole blood was collected in evacuated tubes containing EDTA as the anticoagulant. Phycoerythrin labelled interleukin I (32.5 ng) was added to 25 μΐ EDTA blood for a total reaction volume of 50 μΐ and incubated for 60 minutes at 4 °C. The crythrocytes were then lysed using FACS lysing solution. Unbound phycoerythrin labelled interleukin I was removed by washing the cells with 0.02 mol/1 phosphate buffered 9 g/1 saline solution pH 7.4 and by centrifuging the cells £t 1000 g for five minutes. The cells were resuspended in phosphate buffered saline for final FACS analysis.
Interleukin I inhibitory assay
Phycoerythrin labelled interleukin I (32.5 ng) was added to 500 μg methotrexate or to 50 μg indomethacin or to 800 μg methylprednisolone in a total reaction volume of 25 μΐ and incubated for 30 minutes at room temperature. The methotrexate sample was incubated in opaque tubes because methotrexate is photosensitive. Following this incubation, 25 μΐ EDTA blood was added to give a total reaction volume of 50 μΐ and incubated for 60 minutes at 4 °C. The assay was then continued as described above. The inhibitory assay was repeated using 12.5 -500 μg methotrexate, 200-1200 μg methylprednisolone or 50-120 μg indomethacin. The interaction of methotrexate, methylprednisolone or indomethacin with the binding of interleukin 1 β to its receptor on monocytes, lymphocytes and granulocytes was determined from the decrease in intensity of fluorescence and percentage of cells binding interleukin 1 β.
Controls were carried out with a panel of phycoerythrin-conjugated mouse antHmman monoclonal antibodies against yarious leukocyte differentiation antigens and 500 μg methotrexate, in order to determine whether methotrexate can quench the fluorescence signal of phycoerythrin.
Interleukin 1 receptor integrity assay
An inhibitory assay was started using 32.5 ng phycoerythrin labelled interleukin I , 500 μg methotrexale and 25 μΐ EDTA blood as described above. The assay was stopped after the incubation step with the blood for 60 minutes at 4 °C. The cells were washed 3 times with phosphate buffered saline, then resuspended in phosphate buffered saline for a total volume of 25 μΐ and taken for the binding assay as described above. The results were compared with those of the previously performed inhibitory and binding assays. 
Flow cytometric analysis
Statistical analysis
The data from twenty-five binding and inhibitory assays was checked for significance as follows:
The displacement of the fluorescence intensity due to a diminished phycoerythrin labelled interleukin 1 β binding to its receptor, presented quantitatively in form of histograms, was analysed using the Kolmogofov-Smirnov statistical test (8) . Starting from the two histograms for the same sample before and after additional methotrexate, we computed the sample probability distribution functions Fn,(x) and Fn 2 (x), given by:
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Fni(x r ) = Σ fn,(x) and Fn 2 (x r ) = Σ fn 2 (x) where x r is the abscissa value. In a* how system the abscissa represents 1024 channels, so that 0 < x r < 1024. The graphical presentation of Fn,(x r ) and Fn 2 (x r ) are the summation curves. trations of 12.5 -500 μ£ in the inhibitory assay, we demonstrated that a 50% inhibition of the interleukin I binding is achieved by 75 μg methotrexate for lymphocytes, by 287.5 μ § methotrexate for granulocytes and by 350 μ § methotrexate for monocytes. The assay indicated not only a dose dependent effect of methotrexate on the binding of interleukin I to the interleukin 1 receptor but also a dependence on the cell population. The interleukin I antagonism of methotrexate was first perceptible on lymphocytes then on granulocytes and then on monocytes.
The effect of methotrexate was reversible. Incubation of 500 μg methotrexate with a sixfold interleukin 1 β concentration in the inhibitory assay abolished the ability of methotrexate to block the activity of the cytokine. In these circumstances, interleukin I became bound to the interleukin 1 receptor on target cells. The fluorescence intensity and percentage of interleukin 1 β binding cells were comparable to those in the original binding assay. Methotrexate blocks the activity of interleukin Iß without affecting the integrity of the interleukin 1 receptor on target cells
In the interleukin 1 receptor integrity assay we demonstrated that monocytes, lymphocytes and granulocytes which bound very small amounts of interleukin l ß in the presence of methotrexate, bound interleukin Iß again after removing methotrexate and interleukin l ß from the solution. The binding, measured by fluorescence intensity and percentage of cells stained by phycoerythrin labelled interleukin l ß, was practically identical to that in the original binding assay. Thus, 500 g methotrexate are able to block the binding of 32.5 ng interleukin l ß without affecting the integrity of the interleukin 1 receptor or of the target cells.
Discussion
We investigated the binding of interleukin l ß to the interleukin 1 receptor on the cell surface of monocytes, lymphocytes and granulocytes of healthy volunteers in the presence of methotrexate, by means of phycoerythrin-conjugated cytokine and FACS analysis. According to the literature, the interleukin 1 receptor type II has regulary been found on monocytes, whereas, contrary to our expectations, it was expressed by only 0.2-6.9% of granulocytes.
The binding studies provided direct experimental evidence that methotrexate blocks the binding of interleukin l ß to its receptor on target cells. This effect is dose-dependent. Therefore methotrexate is able to control the interleukin 1 activity by blocking signal transduction between cytokine and target cells. Methotrexate is therefore another interleukin 1 inhibitor such as interleukin 1 receptor antagonist, soluble interleukin 1 receptor or epidermal cell-contra-interleukin 1. Furthermore, the results of the interleukin 1 receptor integrity assay provided experimental evidence that methotrexate functions as an interleukin 1 inhibitor without affecting the integrity of the target cells or the interleukin 1 receptor.
Initially described as a product of activated phagocytic cells, it is now known that interleukin 1 is synthesized by a wide variety of cells. (9) . Its production can be stimulated by agents such as immunocomplexes, complement components, microbial products such as endotoxin, plant lectins or antigens (10) . Interleukin 1 is a proinflammatory cytokine and its pyrogenic effect due to prostaglandin release is well known. Interleukin 1 is a co-growth factor for keratinocytes implicated in acanthosis (11) , it stimulates fibroblasts to synthesize and release collagenase and prostaglandins and stimulates endothelial cells to upregulate adhesion molecules (12, 13) . Interleukin 1 stimulates the immune system directly by activating lymphocytes and indirectly by inducing other cytokines. Interleukin 1 induces in T-cells the production of interleukin 2 as well as the expression of interleukin 2 receptors. Together with interleukin 4 and interleukin 6 interleukin 1 activates B-cells and contributes to the formation of antibodies. In fibroblasts, endothelial cells, macrophages and lymphocytes, interleukin 1 stimulates the production of interferons and haematopoetic colony-stimulating factors. Interleukin 1 and tumour necrosis factor induce the production of each other from monocytes, fibroblasts and endothelial cells. Interleukin 1 stimulates its own production in monocytes (14) , in smooth muscle cells (15) and in endothelial cells (16) . This effect depends upon the concentration of interleukin 1. Furthermore interleukin 1 induces the production of interleukin 8 in dermal fibroblasts, a neutrophil-activating cytokine with a major role in psoriasis (17) , and also in endothelial cells (18) . Interleukin 1 is known to induce the synthesis of interleukin 3 and interleukin 6 and together with interleukin 2 and α Interferon it activates the natural killer cells (19) . An increased interleukin 1 production is implicated in several diseases such as rheumatoid arthritis (9, 20) , septic shock (1, 9), graft versus host disease (21), transplant rejection (22) , acute and chronic leukaemia (9, 23) , psoriasis (24, 25) , tuberculosis (26) , leprosy (27) , cutaneous T-cell lymphoma (28) , inflammatory bowel disease (9) and asthma (9) . Patients with systemic lupus erythematosus have a spontaneous interleukin 1 production by B-cells. B precursor cells express the interleukin 1 receptor. The findings suggest an autocrine mechanism of conversion of precursor B-cells to imrmmoglobulin-producing cells in which interleukin 1 plays a key role (29) . Several clinical studies have shown that low dose methotrexate is efficacious in the treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis (30), psoriasis and psoriatic arthritis (31, 32) , inflammatory bowel disease (33), systemic lupus erythematosus (34), primary biliary cirrhosis (35) , graft versus host disease (36) , but also Sezary syndrome (37) and corticosteroid-dependent asthma (38) , diseases which are meanwhile all known to share an overproduction of interleukin 1. The onset of the antiinflammatory effect of methotrexate was rapid in all treated patients.
Although the mechanism by which high dose methotrexate alters cellular biochemical reactions and exerts its cytotoxic effect is well characterized, the mechanism by which low dose methotrexate interferes with the ongoing inflammatory and immune reactions in such a wide spectrum of diseases remained elusive. In order to demonstrate the presumed immunomodulatory effect of methotrexate several models have been We demonstrated that methotrexate blocks the binding of interleukin I to the interleukin 1 receptor on target cells. The function of methotrexate as an interleukin 1 inhibitor explains its clinical efficiency in a wide spectrum of diseases, which in the meantime have been shown to have in common an overproduction of interleukin 1. The interleukin 1 antagonism of methotrexate leads to a rapid abolition of the ongoing stimulation of the immune system. Both the direct activation of lymphocytes and the cytokine cascade are interrupted. Because of the diversity of cells affected by interleukin 1, methotrexate plays a key role in the therapy as an interleukin 1 inhibitor that specifically modulates the interleukin 1 response without affecting the interleukin 1 receptor or cellular functions.
